{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:21:36Z","timestamp":1740144096710,"version":"3.37.3"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,10,20]],"date-time":"2016-10-20T00:00:00Z","timestamp":1476921600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s40268-016-0146-8","type":"journal-article","created":{"date-parts":[[2016,10,20]],"date-time":"2016-10-20T03:13:26Z","timestamp":1476933206000},"page":"347-353","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Assessment of Distal Radius Bone Mineral Density in Osteoporosis Patients Receiving Denosumab, Including Those with Rheumatoid Arthritis and Those Receiving Oral Glucocorticoids"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2195-5717","authenticated-orcid":false,"given":"Hiroaki","family":"Matsuno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,10,20]]},"reference":[{"issue":"10","key":"146_CR1","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1210\/jc.2013-3795","volume":"99","author":"JW Mandema","year":"2014","unstructured":"Mandema JW, Zheng J, Libanati C, Perez Ruixo JJ. Time course of bone mineral density changes with denosumab compared with other drugs in postmenopausal osteoporosis: a dose-response-based meta-analysis. J Clin Endocrinol Metab. 2014;99(10):3746\u201355.","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"146_CR2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","volume":"11","author":"J Reginster","year":"2000","unstructured":"Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int. 2000;11(1):83\u201391.","journal-title":"Osteoporos Int."},{"issue":"7","key":"146_CR3","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1210\/jc.2013-4175","volume":"99","author":"T Nakamura","year":"2014","unstructured":"Nakamura T, Matsumoto T, Sugimoto T, Hosoi T, Miki T, Gorai I, et al. Clinical Trials Express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT). J Clin Endocrinol Metab. 2014;99(7):2599\u2013607.","journal-title":"J Clin Endocrinol Metab."},{"issue":"10","key":"146_CR4","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1002\/jbmr.149","volume":"25","author":"IR Reid","year":"2010","unstructured":"Reid IR, Miller PD, Brown JP, Kendler DL, Fahrleitner-Pammer A, Valter I, et al. Denosumab Phase 3 Bone Histology Study Group. Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J Bone Miner Res. 2010;25(10):2256\u201365.","journal-title":"J Bone Miner Res."},{"issue":"5","key":"146_CR5","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1210\/jc.2013-4440","volume":"99","author":"BZ Leder","year":"2014","unstructured":"Leder BZ, Tsai JN, Uihlein AV, Burnett-Bowie SA, Zhu Y, Foley K, et al. Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial. J Clin Endocrinol Metab. 2014;99(5):1694\u2013700.","journal-title":"J Clin Endocrinol Metab."},{"issue":"9727","key":"146_CR6","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/S0140-6736(10)60320-0","volume":"375","author":"RM Zebaze","year":"2010","unstructured":"Zebaze RM, Ghasem-Zadeh A, Bohte A, Iuliano-Burns S, Mirams M, Price RI, et al. Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional study. Lancet. 2010;375(9727):1729\u201336.","journal-title":"Lancet."},{"issue":"1","key":"146_CR7","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s00774-009-0099-x","volume":"28","author":"H Yamauchi","year":"2010","unstructured":"Yamauchi H, Fukunaga M, Nishikawa A, Orimo H. Changes in distribution of bone densitometry equipment from 1996 to 2006 in Japan. J Bone Miner Metab. 2010;28(1):60\u20137.","journal-title":"J Bone Miner Metab."},{"key":"146_CR8","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, McShane DJ. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315\u201324.","journal-title":"Arthritis Rheum."},{"issue":"1","key":"146_CR9","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3109\/14397595.2015.1059984","volume":"26","author":"H Matsuno","year":"2016","unstructured":"Matsuno H, Okada M, Sakai Y, Abe C, Katayama K, Sagawa A, et al. The usefulness of a new triple combination treatment utilizing methotrexate, salazosulfapyridine, and bucillamine in rheumatoid arthritis. Mod Rheumatol. 2016;26(1):51\u20136.","journal-title":"Mod Rheumatol."},{"issue":"3","key":"146_CR10","first-page":"e486","volume":"21","author":"JM Albaum","year":"2014","unstructured":"Albaum JM, Youn S, Levesque LE, Gershon AS, Cadarette SM. Osteoporosis management among chronic glucocorticoid users: a systematic review. J Popul Ther Clin Pharmacol. 2014;21(3):e486\u2013504.","journal-title":"J Popul Ther Clin Pharmacol."},{"issue":"5","key":"146_CR11","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1136\/ard.2009.112920","volume":"69","author":"RK Dore","year":"2010","unstructured":"Dore RK, Cohen SB, Lane NE, Palmer W, Shergy W, Zhou L, Denosumab RA Study Group, et al. Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. Ann Rheum Dis. 2010;69(5):872\u20135.","journal-title":"Ann Rheum Dis."},{"key":"146_CR12","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.bone.2013.11.016","volume":"59","author":"RM Zebaze","year":"2014","unstructured":"Zebaze RM, Libanati C, Austin M, Ghasem-Zadeh A, Hanley DA, Zanchetta JR, et al. Differing effects of denosumab and alendronate on cortical and trabecular bone. Bone. 2014;59:173\u20139.","journal-title":"Bone."},{"issue":"1","key":"146_CR13","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00198-009-0930-1","volume":"21","author":"FE Cott\u00e9","year":"2010","unstructured":"Cott\u00e9 FE, Fardellone P, Mercier F, Gaudin AF, Roux C. Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporos Int. 2010;21(1):145\u201355.","journal-title":"Osteoporos Int."},{"issue":"10","key":"146_CR14","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/nrd3229","volume":"9","author":"AL Nelson","year":"2010","unstructured":"Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov. 2010;9(10):767\u201374.","journal-title":"Nat Rev Drug Discov."},{"issue":"5","key":"146_CR15","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1007\/s00198-005-0037-2","volume":"17","author":"WF Lems","year":"2006","unstructured":"Lems WF, Lodder MC, Lips P, Bijlsma JW, Geusens P, Schrameijer N, et al. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial. Osteoporos Int. 2006;17(5):716\u201323.","journal-title":"Osteoporos Int."},{"issue":"6","key":"146_CR16","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1136\/annrheumdis-2012-203171","volume":"73","author":"TW Jensen","year":"2014","unstructured":"Jensen TW, Hansen MS, H\u00f8rslev-Petersen K, Hyldstrup L, Abrahamsen B, Langdahl B, Cimestra Study Group, et al. Periarticular and generalised bone loss in patients with early rheumatoid arthritis: influence of alendronate and intra-articular glucocorticoid treatment. Post hoc analyses from the CIMESTRA trial. Ann Rheum Dis. 2014;73(6):1123\u20139.","journal-title":"Ann Rheum Dis."},{"issue":"6","key":"146_CR17","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1136\/annrheumdis-2015-208052","volume":"75","author":"T Takeuchi","year":"2016","unstructured":"Takeuchi T, Tanaka Y, Ishiguro N, Yamanaka H, Yoneda T, Ohira T, et al. Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial. Ann Rheum Dis. 2016;75(6):983\u201390.","journal-title":"Ann Rheum Dis."},{"issue":"11","key":"146_CR18","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/acr.20295","volume":"2","author":"JM Grossman","year":"2010","unstructured":"Grossman JM, Gordon R, Ranganath VK, Deal C, Caplan L, Chen W, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken). 2010;2(11):1515\u201326.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"6","key":"146_CR19","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/odi.12490","volume":"22","author":"O Fede Di","year":"2016","unstructured":"Di Fede O, Bedogni A, Giancola F, Saia G, Bettini G, Toia F, et al. BRONJ in patients with rheumatoid arthritis: a multicenter case series. Oral Dis. 2016;22(6):543\u20138.","journal-title":"Oral Dis."}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-016-0146-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40268-016-0146-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-016-0146-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T21:38:42Z","timestamp":1498340322000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40268-016-0146-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,20]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["146"],"URL":"https:\/\/doi.org\/10.1007\/s40268-016-0146-8","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"type":"print","value":"1174-5886"},{"type":"electronic","value":"1179-6901"}],"subject":[],"published":{"date-parts":[[2016,10,20]]}}}